Angiomotin p80/p130 ratio: A new indicator of exercise-induced angiogenic activity in skeletal muscles from obese and non-obese rats?

Journal of Physiology

Volumn 587, Issue 16, 2009, Pages 4105-4119

  Roudier, Emilie ^a,b,c   Chapados, Natalie ^c   Decary, Simon ^c   Gineste, Charlotte ^a,b   Le Bel, Catherina ^c   Lavoie, Jean Marc ^c   Bergeron, Raynald ^c   Birot, Olivier ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; ANGIOMOTIN PROTEIN; CYTOCHROME C OXIDASE; PROTEIN P130; PROTEIN P80; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ANGIOMOTIN P130; ANGIOMOTIN P80; ISOPROTEIN; PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; EXERCISE; EXPERIMENTAL MODEL; FEMALE; LIPID DIET; MALE; MUSCLE CELL; MUSCLE REGENERATION; NONHUMAN; OBESITY; PLANTARIS MUSCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SKELETAL MUSCLE; ZUCKER DIABETIC FATTY RAT; CAPILLARY; CELL MIGRATION; ENDOTHELIUM CELL; ENDURANCE TRAINING; IN VIVO STUDY; PLASTICITY; SIGNAL TRANSDUCTION;

ANIMALS; CAPILLARIES; FEMALE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MUSCLE, SKELETAL; MYOFIBRILS; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL ENDURANCE; PHYSICAL EXERTION; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 68949163551     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2009.175554     Document Type: Article

References (39)

1. Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C, Birot O, Ming Y, Kvanta A, Edholm D, Aspenstrom P, Kissil J, Claesson-Welsh L, Shimono A & Holmgren L (2007). Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev 21, 2055-2068.
2. Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE & Doebber TW (2006). Peroxisome proliferators-activated receptor (PPAR)-α agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPARγ agonism. Endocrinology 142, 4252-4262.
3. Birot O & Bigard AX (2003). Responses of the capillary bed in trained skeletal muscle. Sci Sports 18, 1-10.
4. Birot OJ, Koulmann N, Peinnequin A & Bigard XA (2003). Exercise-induced expression of vascular endothelial growth factor mRNA in rat skeletal muscle is dependent on fibre type. J Physiol 552, 213-221.
5. Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP, Laville M, Le Marchand-Brustel Y, Tanti JF, Vidal H (2003). Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52, 1319-1325.
6. Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Meir EGW & Holmgren L (2002). Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 298, 69-77.
7. Bratt A, Birot O, Sinha I, Veitonmaki N, Aase K, Ernkvist M & Holmgren L (2005). Angiomotin regulates endothelial cell-cell junctions and cell motility. J Biol Chem 280, 34859-34869.
8. Carmeliet P (2003). Angiogenesis in health and disease. Nat Med 9, 653-660.
9. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
10. Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmaki N, Bratt A, Dutta A & Holmgren L (2006). p130-Angiomotin associates to actin and controls endothelial cell shape. FEBS J 273, 2000-2011.
11. Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nyström S, Aase K & Holmgren L (2008). Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells. Biochim Biophys Acta 1783, 429-437.
12. Ernkvist M, Persson NL, Audebert S, Lecine P, Sinha I, Liu M, Schlueter M, Horowitz A, Aase K, Weide T, Borg JP, Majumdar A & Holmgren L (2009). The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells. Blood 113, 244-253.
13. Frisbee JC (2002). Obesity, insulin resistance, and microvessel density. Microcirculation 298, 69-77.
14. Frisbee JC, Samora JB, Peterson J & Bryner R (2006). Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 291, H2483-H2492.
15. Frisbee JC, Samora JB & Basile DP (2007). Angiostatin does not contribute to skeletal muscle microvascular rarefaction with low nitric oxide bioavailability. Microcirculation 14, 145-153.
16. Fruttiger M (2002). Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophtalmol Vis Sci 43, 522-527.
17. Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, Masuzaki H, Kim JK, Lee SW & Kim YB (2005). Cell Metab. 2, 119-129.
18. Garcia JG, Verin AD, Herenyiova M, English D (1998). Adherent neutrophils activate endothelial myosin light chain kinase: Role in transendothelial migration. J Appl Physiol 84, 1817-1821.
19. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Physiol 161, 1163-1177.
20. Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson L-M, Musiani P, Lezzi M, Curcio C, Forni G, Cavallo F & Kiessling R (2006). A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 103, 9208-9213.
21. Hudlicka O (1991). What makes blood vessels grow? J Physiol 444, 1-24.
22. Hudlicka O, Brown M & Egginton S (1992). Angiogenesis in skeletal and cardiac muscle. Physiol Rev 72, 369-417.
23. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L & Mansel RE (2006). Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 23, 6-16.
24. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K, Takamatsu I, Sugano N, Hayashi K & Saruta T (2006). Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 20, 169-171.
25. Levchenko T, Aase K, Troyanovsky B, Bratt A & Holmgren L (2003). Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of angiomotin. J Cell Sci 116, 3803-3810.
26. Levchenko T, Bratt A, Arbiser JL & Holmgren L (2004). Angiomotin expression promotes hemangioendothelioma invasion. Oncogene 23, 1469-1473.
27. Levchenko T, Veitonmaki N, Lundkvist A, Gerhardt H, Ming Y, Berggren K, Kvanta A, Carlsson R & Holmgren L (2008). Therapeutic antibodies targeting angiomotin inhibits angiogenesis in vivo. FASEB J 22, 880-889.
28. Matsumura F, Totsukawa G, Yamakita Y, Yamashiro S (2001). Role of myosin light chain phosphorylation in the regulation of cytokinesis. Cell Struct Funct 26, 639-644.
29. Prior BM, Yang HT & Terjung RL (2004). What makes vessels grow with exercise training? J Appl Physiol 97, 1119-1128.
30. Risau W (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
31. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K & Isner JM (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154, 355-363.
32. Rivilis I, Milkiewicz M, Boyd P, Goldstein J, Brown MD, Egginton S, Hansen FM, Hudlicka O & Haas TL (2002). Differential involvement of MMP-2 and VEGF during muscle stretch- versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol 283, H1430-H1438.
33. Sheehan TE, Kumar PA & Hood DA (2004). Tissue-specific regulation of cytochrome c oxidase subunit expression by thyrid hormone. Am J Physiol 286, 968-974.
34. Shimono A & Behringer RR (2003). Angiomotin regulates visceral endoderm movements during mouse embryogenesis. Curr Biol 13, 613-617.
35. Somlyo AV, Phelps C, Dipierro C, Eto M, Read P, Barrett M, Gibson JJ, Burnitz MC, Myers C & Somlyo AP (2003). Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 17, 223-234.
36. Stapleton PA, James ME, Goodwill AG & Frisbee JC (2008). Obesity and vascular dysfunction. Pathophysiology 15, 79-89.
37. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O & Holmgren L (2001). Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152, 1247-1254.
38. Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreault M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, Coldwill K, Starostine A, Metalnikov P & Pawson T (2006). A rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 125, 535-548.
39. White MF (2002). IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283, E413-422.